We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies

This study is currently recruiting participants.
Verified October 2017 by AbbVie
Sponsor:
ClinicalTrials.gov Identifier:
NCT03082209
First Posted: March 17, 2017
Last Update Posted: November 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
AbbVie
  Purpose
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies. The study will consist of 2 segments: Segment I (Dose Escalation) and Segment II (Dose Expansion).

Condition Intervention Phase
Solid Tumors Hematologic Malignancies Drug: ABBV-621 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies

Resource links provided by NLM:


Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Segment 1: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621 [ Time Frame: Up to 21 days ]
    The MTD and/or RP2D of ABBV-621 will be determined during the dose escalation phase (Segment I) of the study.

  • Segment 1: Maximum observed serum concentration (Cmax) of ABBV-621 [ Time Frame: Up to 64 days ]
    Maximum observed serum concentration (Cmax) of ABBV-621.

  • Segment 1: Area under the serum concentration time curve (AUC) of ABBV-621 [ Time Frame: Up to 64 days ]
    Area under the serum concentration time curve (AUC) of ABBV-621.

  • Segment 2: Objective response rate (ORR) [ Time Frame: Approximately 6 months ]
    ORR is defined as the proportion of participants with a response of partial response (PR) or better per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for colorectal cancer (CRC) and other solid tumor participants, or per the International Working Group (IWG) criteria for Acute Myeloid Leukemia (AML) participants, or per the Lugano response criteria for Non-Hodgkin Lymphoma (NHL) participants.

  • Segment 1: Terminal phase elimination rate constant (β) [ Time Frame: Up to 64 days ]
    Terminal phase elimination rate constant (β).

  • Segment 1: Time to Cmax (Tmax) of ABBV-621 [ Time Frame: Up to 64 days ]
    Time to Cmax (Tmax) of ABBV-621.


Secondary Outcome Measures:
  • Segment 2: Dose limiting toxicity (DLT) [ Time Frame: Up to 21 days after first day of study drug administration ]
    A drug-related toxicity is an adverse event or laboratory value outside of the reference range that is judged by the Investigator and/or AbbVie as a "reasonable possibility" of being related to the study drug.

  • QTcF Change from Baseline [ Time Frame: Up to 64 days ]
    QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level


Estimated Enrollment: 92
Actual Study Start Date: March 29, 2017
Estimated Study Completion Date: November 16, 2019
Estimated Primary Completion Date: November 16, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Escalating Arm 1
ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors.
Drug: ABBV-621
Intravenous
Experimental: Escalating Arm 2
ABBV-621 via intravenous administration at escalating dose levels in participants with acute myeloid leukemia (AML).
Drug: ABBV-621
Intravenous
Experimental: Expansion Arm 1
Additional participants with solid tumors will be enrolled in a dose expansion cohort that will further evaluate ABBV-621.
Drug: ABBV-621
Intravenous
Experimental: Expansion Arm 2
Additional participants with colorectal cancer (CRC) will be enrolled in a dose expansion cohort that will further evaluate ABBV-621.
Drug: ABBV-621
Intravenous
Experimental: Expansion Arm 3
Additional participants with AML will be enrolled in a dose expansion cohort that will further evaluate ABBV-621.
Drug: ABBV-621
Intravenous

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a diagnosis of a solid tumor, AML or non-Hodgkin lymphoma (NHL).
  • Must have received at least one prior systemic therapy, and must have relapsed or progressed after, or failed to respond to any/all available effective therapy or therapies.
  • Must have measurable disease (by RECIST 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease.
  • Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2.
  • Must have adequate hematologic, renal and hepatic function.

Exclusion Criteria:

  • Participants with history of brain metastases who have not shown clinical and radiographic stable disease for at least 28 days after definitive therapy.
  • Receipt of any systemic anti-cancer agent, including investigational anti-cancer products, within 21 days prior to study drug administration or 5 half-lives, whichever is longer.
  • Participant with a history of cirrhosis or other indication of significant hepatic function compromise including primary hepatobiliary malignancy (cholangiocarcinoma or hepatocellular carcinoma).
  • Participant with a positive diagnosis of hepatitis A, B, or C.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03082209


Contacts
Contact: AbbVie_Call Center 847.283.8955 abbvieclinicaltrials@abbvie.com

Locations
United States, Connecticut
Yale Cancer Center /ID# 158029 Recruiting
New Haven, Connecticut, United States, 06520
United States, Illinois
The University of Chicago Medical Center /ID# 158030 Recruiting
Chicago, Illinois, United States, 60637
United States, Texas
South Texas Accelerated Research Therapeutics, LLC /ID# 160574 Recruiting
San Antonio, Texas, United States, 78229
Japan
National Cancer Center Hospital East /ID# 160596 Recruiting
Kashiwa-shi, Japan
Netherlands
Erasmus Medisch Centrum /ID# 160869 Recruiting
Rotterdam, Netherlands, 3075 EA
Spain
Hospital Universitario HM Sanchinarro /ID# 165136 Recruiting
Madrid, Spain, 28050
Sponsors and Collaborators
AbbVie
Investigators
Study Director: AbbVie Inc AbbVie
  More Information

Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03082209     History of Changes
Other Study ID Numbers: M15-913
2016-003887-37 ( EudraCT Number )
First Submitted: March 14, 2017
First Posted: March 17, 2017
Last Update Posted: November 2, 2017
Last Verified: October 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by AbbVie:
non-Hodgkin lymphoma
Solid Tumors
acute myeloid leukemia (AML)
Cancer
Hematologic Malignancies
colorectal cancer (CRC)

Additional relevant MeSH terms:
Neoplasms